bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Metformin
 Resources from HONselect
Metformin Still Best Choice for First Type 2 Diabetes Treatment
American College of Physicians updated diabetes guidelines, said second drug can be added

By Randy Dotinga

MONDAY, Jan. 2, 2017 (HealthDay News) -- Newly updated guidelines reaffirm that metformin is the first-line drug for people with type 2 diabetes, and that several other medications -- including newer ones -- can be added if needed.

The recommendations come from the American College of Physicians (ACP). The American Academy of Family Physicians endorsed the new guidelines. The ACP updated the guidelines because of new research into diabetes drugs, and the U.S. Food and Drug Administration approval of new diabetes drugs.

"Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications," ACP president Dr. Nitin Damle said in a college news release.

"The escalating rates of obesity in the U.S. are increasing the incidence and prevalence of diabetes substantially. Metformin has the added benefit of being associated with weight loss," Damle said.

The ACP recommends that if a patient needs to take a second drug by mouth to lower blood sugar levels, physicians should look at adding a sulfonylurea, thiazolidinedione, SGLT-2 inhibitor, or a DPP-4 inhibitor.

Examples of sulfonylurea drugs include glyburide (Diabeta, Glucovance, Micronase), glimepiride, glipizide (Glucotrol) and tolbutamide. Thiazolidinedione drugs include pioglitazone (Actos) and rosiglitazone (Avandia).

SGLT-2 inhibitors include canagliflozin (Invokana), empagliflozin (Jardiance) and dapagliflozin (Farxiga). DPP-4 inhibitors include sitagliptin (Janumet, Januvia) or linagliptin (Jentadueto, Tradjenta). Brand names for metformin include Glumetza, Glucophage, and Fortamet.

"Adding a second medication to metformin may provide additional benefits," Damle said.

"However, the increased cost may not always support the added benefit, particularly for the more expensive, newer medications. ACP recommends that clinicians and patients discuss the benefits, adverse effects, and costs of additional medications," he added.

An estimated 29 million people in the United States have diabetes, according to the U.S. Centers for Disease Control and Prevention.

The guidelines are published in the Jan. 3 issue of the Annals of Internal Medicine.

More information

For more about diabetes medications, try the American Diabetes Association.

SOURCE: American College of Physicians, news release, Jan. 2, 2017

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=718262

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Metformin
Therapeutics
Physicians
Specialty Chemicals and Products
Glyburide
Glipizide
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact